Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies
暂无分享,去创建一个
T. Kadia | F. Ravandi | D. DeAngelo | B. Smith | X. Thomas | J. Delaunay | E. Raffoux | A. Pigneux | C. Zhao | H. Kantarjian | J. Scheuenpflug | W. Guo | W. Guo